Abeona Therapeutics stock rises after receiving permanent J-code for ZEVASKYN By Investing.com
Update: 2025-10-30
Description
Abeona Therapeutics' gene therapy, ZEVASKYN, secures a permanent J-code, simplifying insurance claims and payments. This breakthrough therapy for rare skin condition RDEB gains a unique billing code, J3389, starting January 1, 2026, paving the way for quicker patient access and wider hospital adoption.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
